Literature DB >> 6448023

Biliary elimination of mezlocillin: an experimental and clinical study.

J M Brogard, J Kopferschmitt, J P Arnaud, M Dorner, J La Villaureix.   

Abstract

The biliary elimination of mezlocillin, a new semisynthetic penicillin of the acyl-ureido-penicillin group, was investigated in vitro in rabbit liver preparations and in vivo in humans. Experimentally, mezlocillin recovery in the bile during perfusion of isolted rabbit liver (3 h; n = 5) averaged 20.3% of the administrered dose (10 mg). The mean peak concentration in the bile (758 +/- 129.3 micrograms/ml) was reached between 0.5 and 1 h. Biliary clearance was 169 ml/h. In healthy subjects (n = 5), the concentrations of antibiotic measured in the duodenal fluid during a period of 4 h after intravenous administration of 5 g of mezlocillin ranged between 440 and 637 micrograms/ml. In 10 cholecystectomized patients provided with a T-tube, intramuscular injection of 1 g of mezlocillin resulted in a biliary peak concentration of 295.7 +/- 58.1 micrograms/ml. Mean total amount of antibiotic eliminated in the bile over 12 h corresponded to 2.6% of the administered dose. Assays performed during surgery after intravenous administration of 2 g of mezlocillin (n = 10) showed antibiotic activity of 895 +/- 196 micrograms/ml in the common duct bile and 402 +/- 133 micrograms/ml in the gallbladder bile. These data were compared with the values determined for 11 other beta-lactamines studied under identical conditions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6448023      PMCID: PMC283941          DOI: 10.1128/AAC.18.1.69

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Bile drainage after choledochostomy in man, with some observations on biliary fistula.

Authors:  F F RUNDLE; M H CASS; B ROBSON; M MIDDLETON
Journal:  Surgery       Date:  1955-06       Impact factor: 3.982

2.  Mezlocillin: in vitro studies of a new broad-spectrum penicillin.

Authors:  G P Bodey; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

3.  [Experimental study and human pharmacology of the biliary excretion of a cephalosporin, cephalexin. Therapeutical application].

Authors:  J M Brogard; F Kuntzmann; M Dorner; P Haegele; J Lavillaureix
Journal:  Pathol Biol (Paris)       Date:  1971-12

4.  [New developments and theoretical principles of penicillins].

Authors:  P Schacht
Journal:  Med Welt       Date:  1978-04-28

5.  Biliary excretion of ampicillin: experimental and clinical study.

Authors:  J M Brogard; M Pinget; C Meyer; M Dorner; J Lavillaureix
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

  5 in total
  12 in total

1.  A prospective randomised controlled trial of mezlocillin versus netilmicin in biliary surgery.

Authors:  P Gillen; W Ryan; A L Peel
Journal:  Ann R Coll Surg Engl       Date:  1985-11       Impact factor: 1.891

Review 2.  Antibiotics in the treatment of biliary infection.

Authors:  J S Dooley; J M Hamilton-Miller; W Brumfitt; S Sherlock
Journal:  Gut       Date:  1984-09       Impact factor: 23.059

Review 3.  Biliary tract infections: a guide to drug treatment.

Authors:  J F Westphal; J M Brogard
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

4.  Biliary elimination of apalcillin in humans.

Authors:  J M Brogard; J P Arnaud; J F Blickle; J Lavillaureix
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

5.  Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans.

Authors:  J M Brogard; F Jehl; H Monteil; M Adloff; J F Blickle; P Levy
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of newer antibacterial agents in liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

7.  Dose-dependent pharmacokinetics of mezlocillin in rats.

Authors:  G L Jungbluth; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

8.  Biliary excretion of olsalazine sodium in humans.

Authors:  M Ryde; S Gustavsson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

9.  Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data.

Authors:  F Jehl; M Adloff; H Monteil; J M Brogard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

10.  [Mezlocillin and oxacillin concentrations in the bile of the choledochus].

Authors:  G Brandstätter; P Kratochvil; D Adam; V Chyský
Journal:  Infection       Date:  1982       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.